Thesis icon

Thesis

Cancer cell killing using engineered intracellular antibody fragments

Abstract:

Cancer is one of the leading causes of morbidity and death worldwide, with many either refractory to current therapy regimens or subsequently developing resistance. Novel targeted therapies are therefore needed. Acute T cell leukaemia (T-ALL) is an example of a malignancy without targeted therapies. It has a poor prognosis in adult patients and relapsed disease patients have only a 10% survival rate. T-ALL oncogenes include mutant RAS and aberrantly expressed LMO2, occurring in appro...

Expand abstract

Actions


Access Document


Authors


More by this author
Division:
MSD
Role:
Author

Contributors

Role:
Supervisor
Type of award:
DPhil
Level of award:
Doctoral
Awarding institution:
University of Oxford
UUID:
uuid:2da702d7-3135-4dc3-ae62-2e55fad6c935
Language:
English

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP